drug-repurposing

Rank drug repurposing candidates using multi-source database evidence and evidence hierarchy tiers.

13|5|Updated May 4, 2026

Search Tags:#bioinformatics #drug-discovery #pharmacology #clinical-research #evidence-based-medicine #hcls

Ready to run

npx skills add https://github.com/awslabs/hcls-agent-skills --skill drug-repurposing-awslabs

💬 Prompt for ChatGPT / Claude Chat▼

Please help me install this Agent Skill.
Skill: drug-repurposing
Source: https://github.com/awslabs/hcls-agent-skills/tree/main/skills/drug-repurposing
Command: npx skills add https://github.com/awslabs/hcls-agent-skills --skill drug-repurposing-awslabs

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

This skill addresses the challenge of identifying and validating approved drugs for new therapeutic indications, preventing the pursuit of scientifically weak or clinically untranslatable candidates.

Core Features & Use Cases

Evidence-Based Ranking: Evaluates candidates using a rigorous hierarchy ranging from Mendelian randomization to computational predictions.
Mechanism-of-Action Audit: Validates drug-target interactions, pathway relevance, and directionality to ensure biological plausibility.
Clinical Translatability Assessment: Screens candidates for safety, PK/PD feasibility, and regulatory/IP viability before committing to development.

Quick Start

Use the drug-repurposing skill to evaluate potential candidates for treating idiopathic pulmonary fibrosis by analyzing target-disease associations and ranking them by evidence strength.

Frequently Asked Questions about drug-repurposing

High-intent search queries and answers about installing and using this skill.

FAQPage Schema

How do I rank drug repurposing candidates using multiple bioinformatics databases?▼

Drug repurposing candidates are ranked by integrating target-based and phenotype-based methodologies with evidence from DGIdb, OpenTargets, ChEMBL, and DrugBank to ensure high-confidence therapeutic recommendations based on mechanistic relevance and translatability.

What evidence hierarchy tiers are used for systematic drug repurposing?▼

Systematic drug repurposing evaluates candidates using a rigorous evidence hierarchy ranging from Mendelian randomization to computational predictions, ranking compounds by mechanistic relevance, translatability, and evidence tier strength.

How do I validate drug-target interactions for clinical research workflows?▼

Validating drug-target interactions requires a mechanism-of-action audit that checks pathway relevance and directionality against multi-source database evidence to ensure biological plausibility before clinical development.

Can I assess clinical translatability of approved drugs for new therapeutic indications?▼

Clinical translatability assessment screens approved drug candidates for safety, PK/PD feasibility, and regulatory or IP viability before committing to development for new therapeutic indications.

What's the best way to evaluate drug repurposing candidates for idiopathic pulmonary fibrosis?▼

Evaluating candidates for idiopathic pulmonary fibrosis involves analyzing target-disease associations and ranking them by evidence strength to prevent the pursuit of scientifically weak or clinically untranslatable compounds.

Why do I need to cross-reference DGIdb and OpenTargets data for drug discovery?▼

Cross-referencing DGIdb and OpenTargets data ensures systematic integration of target-based and phenotype-based methodologies, providing multi-source evidence required to generate high-confidence therapeutic recommendations.